FDA approved a premarket approval supplement application for Novocure’s second generation Optune system. The Tumor Treating Fields delivery system is now available to glioblastoma patients in the U.S. The new model features a generator that is less than half the weight and half the size of the generator in the first generation system. Additional improvements...
When President Donald Trump on Feb. 3 signed H.R.7148, a package funding most of the federal government through FY26, many in oncology released a long-held sigh of relief.
